IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS Treating Visceral Leishmaniasis - Preferred Therapy: • Liposomal amphotericin B 2–4 mg/kg IV daily or • Liposomal amphotericin B interrupted schedule (e.g., 4 mg/kg on days 1–5, 10, 17, 24, 31, 38) • Achieve a total dose of 20–60 mg/kg Chronic Maintenance Therapy for Visceral Leishmaniasis Indication: • For patients with visceral leishmaniasis and CD4 count <200 cells/mm3 Preferred Therapy: • Liposomal amphotericin B 4 mg/kg every 2–4 weeks or • Amphotericin B Lipid Complex 3 mg/kg every 21 days Treating Cutaneous Leishmaniasis Preferred Therapy: • Liposomal amphotericin B 2–4 mg/kg IV daily for 10 days or interrupted schedule (e.g., 4 mg/kg on days 1–5, 10, 17, 24, 31, 38) to achieve total dose of 20–60 mg/kg or • Pentavalent antimony (sodium stibogluconate) 20 mg/kg IV or IM daily for 28 days Chronic Maintenance Therapy for Cutaneous Leishmaniasis • May be indicated for immunocompromised patients with multiple relapses #Leishmaniasis #Prevention #Treatment #management #opportunistic #infections #HIVAIDS #pharmacology
